User login
Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.
Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P = .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P = .3398), and objective response rate (46% vs 69%; P = .0938).
Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.
Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.
Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630
Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.
Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P = .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P = .3398), and objective response rate (46% vs 69%; P = .0938).
Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.
Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.
Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630
Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.
Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P = .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P = .3398), and objective response rate (46% vs 69%; P = .0938).
Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.
Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.
Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630